Skip to main content
SpringerLink
Log in

Accumulation of99mTc-HMPAO and99mTc-ECD in rodent and human breast tumor cell linesin vitro

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

The accumulation of99mTc-HMPAO and99mTc-ECD was studied in rat (MatB) and human (MCF-7) breast tumor cell linesin vitro as a function of incubation time. The general pattern was the same for both tracers and both cell lines: the tracer rapidly and extensively accumulated in the cells but a plateau was reached in 15–30 minutes. Accumulation of HMPAO was higher than that of ECD, did not show a difference between rat and human cells, and correction of HMPAO data for intracellular sequestration and extracellular metabolism resulted in a linear increase in accumulation with time. In contrast, accumulation of ECD was ∼ 2-fold higher in human cells than in rat cells but after correction for sequestration and metabolism a plateau remained. These experiments show differences between HMPAO and ECD in their accumulation and retention in breast cancer cellsin vitro and support that the need for further work on the potential clinical role for HMPAO in tumor characterization.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Neirinckx RD, Canning LR, Piper IM, Nowotnik DP, Pickett RD, Holmes RA, et al. Technetium-99m d,l-HM-PAO: A new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion.J Nucl Med 28: 191–202, 1987.

    PubMed  CAS  Google Scholar 

  2. Vallabhajosula S, Zimmerman RE, Picard M, Stritzke P, Mena I, Hellman RS, et al. Technetium-99m ECD: A new brain imaging agent:In vivo kinetics and biodistribution studies in normal human subjects.J Nucl Med 30: 599–604, 1989.

    PubMed  CAS  Google Scholar 

  3. Neirinckx RD, Burke JF, Harrison RC, Forster AM, Andersen AR, Lassen NA. The retention mechanism of technetium-99m-HM-PAO: Intracellular reaction with glutathione.J Cereb Blood Flow Metab 8: S4-S12, 1988.

    PubMed  CAS  Google Scholar 

  4. Ballinger JR, Reid RH, Gulenchyn KY. Techne!ium-99m HM-PAO stereoisomers: Differences in interaction with glutathione.J Nucl Med 29: 1998–2000, 1988.

    PubMed  CAS  Google Scholar 

  5. Jacquier-Sarlin MR, Polla BS, Slosman DO. Oxide-reductive state: The major determinant for cellular retention of technetium-99m-HMPAO.J Nucl Med 37: 1413–1416, 1996.

    PubMed  CAS  Google Scholar 

  6. Walovitch RC, Cheesman EH, Maheu LJ, Hall KM. Studies of the retention mechanism of the brain perfusion imaging agent99mTc-bicisate (99mTc-ECD).J Cereb Blood Flow Metab 14: S4-S11, 1994.

    PubMed  CAS  Google Scholar 

  7. Jacquier-Sarlin MR, Polla BS, Slosman DO. Cellular basis of ECD brain retention.J Nucl Med 37: 1694–1697, 1996.

    PubMed  CAS  Google Scholar 

  8. Inoue Y, Momose T, Watanabe T, Ohtake T, Nishikawa J, Sasaki Y. Properties of enzyme to catalyze Tc-99m ECD (abstr).J Nucl Med 37: 189P, 1996.

    Google Scholar 

  9. Grunwald F, Menzel C, Pietsch T, Pavics L, Hufnagel A, Biersack H-J. Increased technetium-99m-HMPAO uptake in Grade II astrocytoma.J Nucl Med 26: 804–806, 1995.

    Google Scholar 

  10. Suess E, Malessa S, Ungersbock K, Kitz P, Podreka I, Heimberger K, et al. Technetium-99m-d,l-hexamethylpropyleneamine oxime (HMPAO) uptake and glutathione content in brain tumors.J Nucl Med 32: 1675–1681, 1991.

    PubMed  CAS  Google Scholar 

  11. Shih WJ, Coupai J, Magoun S. The biodistribution of technetium-99m-hexamethylpropylene amine oxime.Semin Nucl Med 24: 180–183, 1994.

    Article  PubMed  CAS  Google Scholar 

  12. Tanada S, Murase K, Inoue T, Sugawara Y, Miki H, Okumura A, et al. Comparison of kinetics in brain tumors between Tc-99m ECD and Tc-99m HMPAO with dynamic brain SPECT and compartmental model (abstr).J Nucl Med 33: 969–970, 1992.

    Google Scholar 

  13. Hirano T, Suzuki H, Higuchi T, Watanabe N, Oriuchi N, Shibazaki T, et al. Grade II astrocytoma visualized by technetium-99m-ECD SPECT.J Nucl Med 37: 273–275, 1996.

    PubMed  CAS  Google Scholar 

  14. Schecter RL, Woo A, Duong M, Batist G.In vivo andin vitro mechanisms of drug resistance in a rat mammary carcinoma model.Cancer Res 51: 1434–1442, 1991.

    PubMed  CAS  Google Scholar 

  15. Ballinger JR, Cowan DSM, Boxen I, Zhang ZM, Rauth AM. Effect of hypoxia on the accumulation of technetium-99m-glucarate and technetium-99m-gluconate by Chinese hamster ovary cellsin vitro.J Nucl Med 34: 242–245, 1993.

    PubMed  CAS  Google Scholar 

  16. Ballinger JR, Sheldon KM, Boxen I, Erlichman C, Ling V. Differences between accumulation of99mTc-sestamibi and201Tl-thallous chloride in tumour cells: Role of P-glycoprotein.Quart J Nucl Med 39: 122–128, 1995.

    CAS  Google Scholar 

  17. Ballinger JR, Hua HA, Berry BW, Firby P, Boxen I.99mTc-Sestamibi as an agent for imaging P-glycoprotein-mediated multidrug resistance:In vitro andin vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant.Nucl Med Commun 16: 253–257, 1995.

    Article  PubMed  CAS  Google Scholar 

  18. Suess E, Huck S, Reither H, Hortnagl H, Angelberger P. Uptake mechanism of technetium-99m-d,l-HMPAO in cell cultures of the dissociated postnatal rat cerebellum.J Nucl Med 33: 108–114, 1992.

    PubMed  CAS  Google Scholar 

  19. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells.J Biol Chem 261: 15544–15549, 1986.

    PubMed  CAS  Google Scholar 

  20. Ballinger JR, Wan Min Kee J, Rauth AM.In vitro andin vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia.J Nucl Med 37: 1023–1031, 1996.

    PubMed  CAS  Google Scholar 

  21. El-Shirbiny AM, Sadek S, Owunwanne A, Yacoub T, Suresh L, Abdel-Dayem HM. Is99mTcm hexamethylpropyleneamine oxime uptake in the tissues related to glutathione cellular content?Nucl Med Commun 10: 905–911, 1989.

    Article  PubMed  CAS  Google Scholar 

  22. Sasaki T, Toyama H, Oda K, Ogihara-Umeda I, Nishigori H, Senda M. Assessment of antioxidative ability in brain: Technetium-99m-meso-HMPAO as an imaging agent for glutathione localization.J Nucl Med 37: 1698–1701, 1996.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncologic Imaging and Experimental Therapeutics, Ontario Cancer Institute, Canada

    James R. Ballinger, Jill Duncan, H. Annie Hua & Masanori Ichise

  2. Division of Nuclear Medicine, Mount Sinai Hospital, Canada

    James R. Ballinger, Jill Duncan, H. Annie Hua & Masanori Ichise

  3. Faculties of Pharmacy and Medicine, University of Toronto, Canada

    James R. Ballinger, Jill Duncan, H. Annie Hua & Masanori Ichise

Authors
  1. James R. Ballinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jill Duncan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Annie Hua
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masanori Ichise
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James R. Ballinger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ballinger, J.R., Duncan, J., Hua, H.A. et al. Accumulation of99mTc-HMPAO and99mTc-ECD in rodent and human breast tumor cell linesin vitro . Ann Nucl Med 11, 95–99 (1997). https://doi.org/10.1007/BF03164816

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03164816

Key words

Search

Navigation